Overall, these findings define a mechanism by which 1, 25-(OH)<sub>2</sub>D<sub>3</sub> reduces ECM accumulation and suppresses the TGF-β-SMAD3-VDR pathway in HTMCs, thus protecting the cells from oxidative stress, suggesting 1, 25-(OH)<sub>2</sub>D<sub>3</sub> might be a potential therapeutic for glaucoma.
This study investigated whether vitamin D receptor gene polymorphisms are altered in primary open-angle glaucoma subjects carrying the risk allele, and whether vitamin D deficiency is an important factor in the development of glaucoma.